Aloxi® Injection (Palonosetron Hydrochloride)
Compared with: Blackmores Conceive Well Gold 28 Tablets + 28 Capsules
Aloxi® Injection (Palonosetron 0.25 mg) is a highly selective 5‑HT₃ receptor antagonist for the prevention of acute and delayed chemotherapy‑induced nausea and vomiting (CINV). Its unique binding affinity and long half‑life provide up to 72 hours of protection, improving patient comfort and adherence to antiemetic regimens.
Palonosetron Hydrochloride – 0.25 mg per 0.25 mg/5 mL vial

Other Popular and Common Names
5‑HT₃ Receptor Antagonist
Palonosetron IV
Aloxi® 0.25 mg Injection

CINV Prophylaxis Injection
Postoperative Nausea and Vomiting Prophylaxis (PONV off‑label)
Palonosetron binds with high affinity to 5‑hydroxytryptamine type 3 (5‑HT₃) receptors on vagal nerve terminals and centrally in the chemoreceptor trigger zone. It prevents serotonin‑mediated activation of the vomiting reflex. Its allosteric binding and receptor internalization confer a prolonged duration of action (>40 hours).
Prevention of acute CINV (within 24 hours of chemotherapy)
Prevention of delayed CINV (24–72 hours after chemotherapy)
Off‑Label: Prophylaxis of postoperative nausea and vomiting (PONV) under anesthesiologist guidance
Indication Dose Timing Notes
Acute & Delayed CINV (Adults) 0.25 mg IV as a single dose Administer 30 minutes prior to chemotherapy Dilute in 5 mL normal saline; inject over 30 seconds
PONV (Off‑Label) 0.075 mg IV At induction of anesthesia Lower dose recommended for PONV
Pediatric Use: Not routinely recommended; limited data in children <18 years.
Renal/Hepatic Impairment: No dosage adjustment required.
Form: Sterile aqueous solution in single‑use vial
Strength: Palonosetron 0.25 mg/5 mL
Route: Intravenous bolus injection
Legal Status: Prescription Only Medicine
Pregnancy: Category B1 – Use only if clearly needed; animal data show no fetal risk, but human data are limited.

Breastfeeding: Unknown excretion in human milk; weigh benefits against potential risks.

Children: Safety and efficacy not established in patients <18 years.

Elderly: No dosage adjustment; monitor for constipation and headache.

Side Effects
Common (≥1 %):HeadacheConstipation Dizziness
Fatigue
QT interval prolongation (caution in patients with risk factors)
Hypersensitivity reactions (rash, bronchospasm, anaphylaxis)
Transient increases in liver enzymes
QT Prolongation: Use with caution in patients with congenital long QT syndrome or electrolyte abnormalities. Monitor ECG in high‑risk patients.

Hypersensitivity: Discontinue if signs of severe allergic reaction occur.

Serotonin Syndrome: Rare when combined with other serotonergic drugs; monitor for agitation, hyperreflexia, and autonomic instability.

Constipation: Encourage adequate hydration and dietary fiber.
Therapeutic Class: Antiemetic

Pharmacologic Class: 5‑HT₃ Receptor Antagonist

Legal Category: Prescription Only
Apomorphine: Concomitant use contraindicated due to severe hypotension risk.

Other QT‑Prolonging Agents (e.g., certain antiarrhythmics, antipsychotics): Additive risk of arrhythmia.

Serotonergic Agents (e.g., SSRIs, SNRIs, MAO‑inhibitors): Rare risk of serotonin syndrome; monitor closely.

Chemotherapeutic Agents: No significant interaction; co‑administration standard in antiemetic protocols
PALONOSE Study (2003): Demonstrated superior control of delayed CINV versus ondansetron (70 % vs. 50 % complete response at 48–72 hours).

ASCO Guidelines (2017): Recommend palonosetron as preferred 5‑HT₃ antagonist in high‑emetogenic chemotherapy regimens.

Comparison with Blackmores Conceive Well Gold
Aloxi® Injection prevents chemotherapy‑ and surgery‑related nausea, whereas Blackmores Conceive Well Gold supports preconception nutritional health. Patients undergoing fertility‑preserving chemotherapy may require Aloxi® to maintain comfort, then transition to Conceive Well Gold when planning pregnancy post‑treatment.

FAQs – Aloxi® Injection (Palonosetron)
Q1. How long does Aloxi® protect against nausea?
A: A single 0.25 mg IV dose controls acute and delayed CINV for up to 72 hours.

Q2. Can I receive Aloxi® for postoperative nausea?
A: Off‑label use at 0.075 mg IV during anesthesia induction is common; consult your anesthesiologist.

Q3. Do I need ECG monitoring?
A: Only if you have risk factors for QT prolongation (e.g., electrolyte disturbances, concurrent QT‑prolonging drugs).

Q4. Can Aloxi® be mixed with other antiemetics?
A: Yes. It is often combined with dexamethasone and an NK₁ antagonist (e.g., aprepitant) for multimodal CINV prophylaxis.

Q5. Is it safe in kidney disease?
A: No dose adjustment is required in renal impairment.

Q6. How fast should it be injected?
A: Over at least 30 seconds; rapid bolus may increase risk of QT prolongation.

Q7. Can I breastfeed after Aloxi®?
A: Exercise caution; discuss risks and benefits with your physician.
Aloxi Injection, Palonosetron IV, CINV Prevention, Delayed Nausea Control, 5-HT₃ Antagonist, Oncology Antiemetic, Chemotherapy Side‑Effect Management, QT‑Safety Antiemetic, EZ Chemist, ASCO‑Recommended Antiemetic